RKLB
Rocket Lab USA, Inc.
RKLB offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
SRTA
Strata Critical Medical, Inc.
SRTA has the edge over RKLB overall, supported by lower modeled downside and stronger fundamentals.
RKLB Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
RKLB's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
SRTA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Stable | |
| Strong |
SRTA's revenue and balance sheet are currently healthy, and its cash flow is stable, but its profitability is under pressure.
RKLB PE Valuation
RKLB has no meaningful PE right now: it lost money over the past year.
SRTA PE Valuation
SRTA has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 100x next year's earnings.
RKLB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect RKLB's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
SRTA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect SRTA to return to profit, with revenue growing.
RKLB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.36 | +$0.03 |
| Q2 2026 | -$0.27 | +$0.19 |
| Q1 2026 | -$0.32 | +$0.09 |
| Q4 2025 | -$0.37 | +$0.01 |
| Q3 2025 | -$0.39 | -$0.02 |
| Q2 2025 | -$0.46 | -$0.11 |
| Q1 2025 | -$0.41 | -$0.04 |
| Q4 2024 | -$0.38 | $0.00 |
RKLB is still losing money, but less than at its worst: $0.36 per share over the past year, against $0.46 at its worst in mid-2025.
SRTA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.06 | — |
| Q3 2026 | -$0.29 | -158% |
| Q2 2026 | $0.50 | +$0.73 |
| Q1 2026 | $0.57 | +$0.90 |
| Q4 2025 | $0.50 | +$0.85 |
| Q3 2025 | $0.50 | +$1.19 |
| Q2 2025 | -$0.23 | +$0.43 |
| Q1 2025 | -$0.33 | +$0.35 |
| Q4 2024 | -$0.35 | +$0.41 |
SRTA has the edge over RKLB on earnings, with more consistent year-over-year improvement.
RKLB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $267.8M | +73% |
| Q2 2026 | $234.1M | +62% |
| Q1 2026 | $200.3M | +63% |
| Q4 2025 | $179.7M | +36% |
| Q3 2025 | $155.1M | +48% |
| Q2 2025 | $144.5M | +36% |
| Q1 2025 | $122.6M | +32% |
| Q4 2024 | $132.4M | +121% |
RKLB has the edge over SRTA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -30% | +8.5 points |
| Q2 2026 | -25% | +17 points |
| Q1 2026 | -28% | +20 points |
| Q4 2025 | -28% | +11 points |
| Q3 2025 | -38% | +12 points |
| Q2 2025 | -41% | -0.5 points |
| Q1 2025 | -48% | -1.9 points |
| Q4 2024 | -39% | +41 points |
RKLB's operating margin was −30% last quarter, up 8.5 points from the same quarter a year ago.
SRTA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $74.1M | +50% |
| Q2 2026 | $72.5M | +2.4% |
| Q1 2026 | $67.4M | +24% |
| Q4 2025 | $66.8M | +23% |
| Q3 2025 | $49.3M | -34% |
| Q2 2025 | $70.8M | +4.2% |
| Q1 2025 | $54.3M | +5.4% |
| Q4 2024 | $54.4M | +14% |
SRTA's revenue has grown year over year for four quarters in a row: $74M last quarter, up 50% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -5.2% | +6.2 points |
| Q2 2026 | -7.5% | -0.5 points |
| Q1 2026 | -4.4% | +9.6 points |
| Q4 2025 | -9.6% | +5.8 points |
| Q3 2025 | -11% | -6.7 points |
| Q2 2025 | -7% | +11 points |
| Q1 2025 | -14% | +5.2 points |
| Q4 2024 | -15% | +60 points |
SRTA has the edge over RKLB on profitability, with a higher operating margin.
RKLB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$23.9M | +$45.5M |
| Q2 2026 | -$110.1M | -$54.8M |
| Q1 2026 | -$77.4M | +$5.5M |
| Q4 2025 | -$114.2M | -$90.2M |
| Q3 2025 | -$69.4M | -$27.5M |
| Q2 2025 | -$55.3M | -$26.9M |
| Q1 2025 | -$82.9M | -$61.1M |
| Q4 2024 | -$23.9M | +$28.7M |
RKLB has burned cash in almost every quarter: −$326M over the past year, against −$232M the year before.
SRTA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $9.1M | +$49.2M |
| Q2 2026 | $3.2M | +$8.6M |
| Q1 2026 | -$1.3M | +$1.6M |
| Q4 2025 | -$10.2M | -$3.8M |
| Q3 2025 | -$40.1M | -$37.2M |
| Q2 2025 | -$5.4M | +$2.4M |
| Q1 2025 | -$2.9M | +$13.5M |
| Q4 2024 | -$6.3M | +$3M |
SRTA has the edge over RKLB on cash generation, producing positive trailing cash flow while its opponent burns cash.
RKLB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.6% | +22.6M shares |
| 1 year | +23% | +124M shares |
| 3 years | +35% | +168M shares |
| 5 years | +46% | +204M shares |
RKLB has 652M diluted shares, up 23% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
SRTA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.4% | +2.1M shares |
| 1 year | +7.1% | +5.8M shares |
| 3 years | +9% | +7.3M shares |
| 5 years | +71% | +36.7M shares |
| Available history | +977% | +80.1M shares |
SRTA has the edge over RKLB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q4 2019 | — |
RKLB Net Leverage
RKLB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SRTA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -10.7x | Net Cash |
SRTA has more cash than debt.
RKLB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.8 | Neutral |
| Stochastic | 27.6 | Neutral |
RKLB's weekly RSI is 47 (neutral) and its Stochastic is 28 (neutral).
SRTA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.4 | Neutral |
| Stochastic | 49.4 | Neutral |
SRTA's weekly RSI is 57 (neutral) and its Stochastic is 49 (neutral).
RKLB PE vs Industrials Sector
RKLB has no meaningful PE right now: it lost money over the past year.
SRTA PE vs Industrials Sector
| Metric | SRTA | Sector median | Relative |
|---|---|---|---|
| PE | 8.9x | 24x | 63% below |
| PE % | 20 | 58 | 38 pts below |
SRTA has no meaningful PE right now: it lost money over the past year.
RKLB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $61.4 | 4.3% above |
| 20 week MA | $68.1 | 5.9% below |
| 50 week MA | $77.6 | 17% below |
| 100 week MA | $56.5 | 13% above |
| 200 week MA | $31.4 | 104% above |
RKLB's trend is mixed: it's above three of its five weekly moving averages, and 104% above its 200-week average.
SRTA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.95 | 17% above |
| 20 week MA | $5.25 | 9.9% above |
| 50 week MA | $5.11 | 13% above |
| 100 week MA | $4.53 | 27% above |
| 200 week MA | $3.94 | 46% above |
SRTA has the edge over RKLB on trend strength, trading above more of its moving averages.
RKLB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.82 | $10.3 | +4.9% |
| 2021 | $10.3 | $12.0 | +17% |
| 2022 | $12.0 | $3.77 | -69% |
| 2023 | $3.77 | $5.53 | +47% |
| 2024 | $5.53 | $27.2 | +392% |
| 2025 | $27.2 | $70.7 | +160% |
| 2026 YTD | $70.7 | $64.1 | -9.3% |
RKLB's yearly returns have swung widely, from +392% in 2024 to −69% in 2022. It's down 9.3% so far in 2026.
SRTA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.83 | $11.0 | +12% |
| 2021 | $11.0 | $9.25 | -16% |
| 2022 | $9.25 | $3.50 | -62% |
| 2023 | $3.50 | $3.53 | +0.9% |
| 2024 | $3.53 | $4.41 | +25% |
| 2025 | $4.41 | $4.87 | +10% |
| 2026 YTD | $4.87 | $5.77 | +18% |
SRTA has the edge over RKLB on returns for 2026, with the stronger performance.